|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs and SGLT2i are now advocated as second-line agents in European and US guidelines for management of both hyperglycaemia and for primary prevention of cardiovascular disease in people with T2DM.
|
31551292 |
2020 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, fecal microbiota transplantation (FMT) using fecal material from metformin-treated mice was found to upregulate the expression of GLP-1 and pattern-recognition receptors TLR1 and TLR4 for the improvement in hyperglycemia caused by a high-fat diet.
|
31501716 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although glucagon-like peptide 1- (GLP-1-) based therapy of hyperglycemia in burn injury has shown great potential in clinical trials, its safety is seldom evaluated.
|
30800001 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, GLP-1RAs effectively reduced hyperglycemia in patients with mild or moderately impaired kidney function in the limited number of studies to date.
|
31318152 |
2019 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLP-1 receptors are involved in the liraglutide-induced relaxation of branched arteries, under normoglycaemic conditions, while GLP-1 inhibition of vascular superoxide levels contributes to GLP-1 receptor-independent potentiation of endothelium-dependent vasodilatation in hyperglycaemia.
|
30403290 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 antagonist significantly blocked the inhibitory effect of IES on hyperglycemia from 15 to 120 min (all p < 0.05).
|
30728346 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that GLP-Cr(III) complex could be used as potential functional food ingredients for the prevention or treatment of hyperglycemia and hyperlipidemia.
|
31401268 |
2019 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed the impact of PARP-1 inhibition on <i>C. elegans</i> health in the setting of hyperglycemia and on glucose-stimulated GLP-1 secretion in human intestinal cells.
|
29392078 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on our previous finding that GLP-1 could control hyperglycemia by increasing insulin secretion and inhibiting β-cell apoptosis in severe scald injuries, this study further confirmed that Exendin-4 could increase glycemic control following severe scald by preserving the histology of β cells in pancreatic islets and inhibiting their apoptosis.
|
30211851 |
2018 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sitagliptin, a dipeptidyl peptidase-IV inhibitor (DPP-4), sustains activity of the incretin hormones GLP-1 and GIP and improves hyperglycemia in Type 2 diabetes mellitus (T2DM).
|
29138226 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
There have been several new treatment approaches established for the management of hyperglycemia in type 2 diabetes (T2D), with treatment guidelines listing both glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and basal insulin therapies as considerations for patients who have failed to control their blood glucose with oral antidiabetic agents.
|
29492243 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results identify D-allulose as prominent GLP-1 releaser that acts via vagal afferents to restrict feeding and hyperglycemia.
|
29317623 |
2018 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are injectable agents used for the treatment of hyperglycemia in type 2 diabetes.
|
28274140 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incretin hormones (glucagon-like peptide-1 [GLP-1] and gastric inhibitory polypeptide [GIP]) may play a role in the development of glucose intolerance and hyperglycemia in patients with hyperthyroidism.
|
28452237 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pasireotide-induced hyperglycemia occurs early, within the first 3 months of treatment, due to a decrease in insulin secretion secondary to a fall in secretion of GLP-1 and GIP, and potentially also due to a direct inhibitory effect of pasireotide on beta cells.
|
28579289 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide one (GLP-1)-based therapies for reducing hyperglycemia in type 2 diabetic patients are efficient, though some individuals develop GLP-1 resistance.
|
28683295 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
|
27629433 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Injectable therapies, including prandial insulin analogs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), and the amylin analog pramlintide, all effectively target postprandial hyperglycemia.
|
28118069 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
[6]-Gingerol, from Zingiber officinale, potentiates GLP-1 mediated glucose-stimulated insulin secretion pathway in pancreatic β-cells and increases RAB8/RAB10-regulated membrane presentation of GLUT4 transporters in skeletal muscle to improve hyperglycemia in Lepr<sup>db/db</sup> type 2 diabetic mice.
|
28793909 |
2017 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, ursolic acid is more effective than betulinic acid in reduction of hyperglycemia and increase of GLP-1 secretion.
|
28756460 |
2017 |
|
Hyperglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate alterations in gene expression resulting from incubation with GLP-1 (7-36) or hyperglycaemia, the RNA expression levels of miR-23a, PGC-1α, Bak, Bax and UCP2 were quantified using real-time PCR.
|
26315270 |
2015 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether oral administration of human commensal bacteria engineered to secrete GLP-1(1-37) could ameliorate hyperglycemia in a rat model of diabetes by reprogramming intestinal cells into glucose-responsive insulin-secreting cells.
|
25626737 |
2015 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we provide evidence that hyperglycaemia per se, the genetic background and their interaction result in the development of GLP1 resistance of the β-cell.
|
22928568 |
2012 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, Zac1 expression did not interfere with the signaling of the glucagon-like peptide 1 receptor (GLP-1R), and the GLP-1 analog liraglutide improved hyperglycemia in transplanted experimental diabetic mice.
|
22547676 |
2012 |
|
Hyperglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion.
|
11124853 |
2000 |